cognitive cybersecurity intelligence
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).
Talquetamab is…
Source: www.labiotech.eu – Read more
Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.
You Don’t Have to Update to iOS 26 to Protect Your iPhone From DarkSword Malware Lifehacker
You Don’t Have to Update to iOS 26 to Protect Your iPhone From DarkSword Malware lifehacker.com
CERT-UA Impersonation Campaign Spread AGEWHEEZE Malware to 1 Million Emails The Hacker News
Over half a million lines of Claude Code source code was leaked, with the company attributing the blunder to human error
